SMH-Venice Physician Newsletter – October 2024
Message on behalf of SMH-Venice Chief of Staff Dr. Scott Perrin
Thank you all for attending the annual medical staff meeting! It was wonderful to see everyone, both in person and on Webex. This past year has brought many successes as well as challenges for SMH Venice. We look forward to the coming year as we continue working together to ensure the successful growth and expansion of the hospital.
Please take some time to review the important items in the newsletter below..
#1 Covid 19 Treatment Updates
COVID-19 Therapy Informed Consent
- During the most recent legislative session, the Florida Senate passed a new law that requires informed consent for all patients receiving COVID therapeutics
- This includes Dexamethasone (for COVID), Remdesivir, Baricitinib, and Tocilizumab
- We have made several changes to the COVID Non-ICU and ICU Patient Treatment order sets to make it easier for the provider to document they discussed the benefits, risks, and alternatives with the patient or caregiver/li>
- Please note, it is NOT our responsibility to ensure or police compliance with the documentation standard
- We can certainly point them in the right direction if a physician or APP has any questions about the new process
- Note: Education will be sent out to medical staff via the Medical Staff office very soon
- The two COVID therapy order sets now have dexamethasone and consults for remdesivir, baricitinib, and tocilizumab. When they select the drug or consult, an attestation order will automatically be selected
Remdesivir Updates
- We have enhanced the process for ordering Remdesivir. There are now two consult options available to order in the set, a 3-day regimen and a 5-day regimen.
- For patients with mild-moderate disease, the 3-regimen has been shown to be safe and effective
- Patients with severe disease should receive a 5-day regimen
- Remdesivir no longer requires renal function assessment OR monitoring
- Based on recent clinical studies, no dosage adjustment is recommended in patients with any degree of renal impairment, including those on dialysis
- There is no longer a warning or precaution on the use of remdesivir in patients with renal impairment
- Per the package insert, baseline PT and LFTs are recommended and can be ordered per protocol if needed
- The consult no longer needs a daily follow-up and has been changed to an ONCE order
#2 HIM Newsletter
Please click on the link below to read the Health Information Newsletter
HIM Newsletter - Partnering for Quality
#3 Antibiotic Allergy Alerts and Surgical Prophylaxis Update
Please click on the link below to read the updates related to Antibiotic Allergy and Surgical Prophylaxis
Antibiotic Allergy Alerts and Surgical Prophylaxis Update.
#4 Quality Quarterly Newsletter
Please click on the link below to read the Quality Quarterly Newsletter
Quality Quarterly Newsletter
#5 Annual Mandatory CEU available in HealthStream
Please click on the link below for information on accessing the annual mandatory continuing education in HealthStream.
Annual Mandatory Continuing Education
#6 How to be notified on Upcoming CEU Activities
The Continuing Education Program of SMHCS is pleased to now offer a way to be notified of upcoming Continuing Education activities such as Grand Rounds and other great CE offerings.
Or CLICK HERE
Thank you,
Scott Perrin, MD
Chief of Staff